Commodore Capital LP
13F holdings for Q2 2026 · NEW YORK, NY · filed August 14, 2026
Commodore Capital LP reported $1.7B in 13F securities across 33 holdings for Q2 2026, in a Form 13F filed August 14, 2026. The largest positions were RLAY (13.4%), ELVN (9.9%), Alkermes PLC (9.4%). Reported value fell 2.9% from the quarter before. It opened 5 new positions, added to 6, trimmed 9 and sold out of 8.
- 13F value Q2 2026
- $1.7B
- Holdings
- 33
- Change vs prior quarter
- -2.9%
- Rank by 13F value
- #1,817
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Top holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| RLAY Relay Therapeutics Inc. | $225M | 13.4% | 12,000,000 | -29.4% | Trimmed |
| ELVN Enliven Therapeutics Inc. | $166M | 9.9% | 3,275,000 | 0% | Unchanged |
| Alkermes PLC | $157M | 9.4% | 3,000,000 | -28.6% | Trimmed |
| COGT Cogent Biosciences Inc. | $118M | 7.0% | 3,050,000 | +5.6% | Added |
| AMLX Amylyx Pharmaceuticals Inc. | $101M | 6.0% | 5,650,000 | 0% | Unchanged |
| DFTX Definium Therapeutics Inc. | $94.1M | 5.6% | 2,000,000 | 0% | Unchanged |
| SYRE Spyre Therapeutics Inc. | $75.2M | 4.5% | 846,786 | -55.7% | Trimmed |
| ANRO Alto Neuroscience Inc. | $71.9M | 4.3% | 2,723,196 | 0% | Unchanged |
| TNGX Tango Therapeutics Inc. | $70.3M | 4.2% | 2,250,000 | New | New |
| EYPT EyePoint Inc. | $65.8M | 3.9% | 4,600,000 | +62.8% | Added |
| TYRA Tyra Biosciences Inc. | $59.9M | 3.6% | 1,875,000 | -24.2% | Trimmed |
| Damora Therapeutics Inc | $50.4M | 3.0% | 1,939,000 | 0% | Unchanged |
| CLDX Celldex Therapeutics Inc. | $50.2M | 3.0% | 1,350,000 | -49.9% | Trimmed |
| Pharvaris NV | $49.3M | 2.9% | 1,425,000 | -25.7% | Trimmed |
| LBRX LB Pharmaceuticals Inc | $48.7M | 2.9% | 1,500,000 | 0% | Unchanged |
| ASMB Assembly Biosciences Inc. | $38.9M | 2.3% | 1,415,000 | +41.5% | Added |
| EDIT Editas Medicine Inc. | $28.8M | 1.7% | 8,889,000 | New | New |
| KYMR Kymera Therapeutics Inc. | $28.7M | 1.7% | 250,000 | -66.7% | Trimmed |
| CATX Perspective Therapeutics Inc. | $21.6M | 1.3% | 6,336,782 | 0% | Unchanged |
| IPSC Century Therapeutics Inc. | $21.3M | 1.3% | 8,695,652 | 0% | Unchanged |
| Zura Bio LTD | $19.2M | 1.1% | 3,250,000 | 0% | Unchanged |
| AVTX Avalo Therapeutics Inc. | $18.8M | 1.1% | 1,018,319 | +110.8% | Added |
| Inflarx Nv | $16.4M | 1.0% | 7,300,000 | New | New |
| ANTX AN2 Therapeutics Inc. | $14.2M | 0.8% | 2,933,680 | +25.7% | Added |
| Nuvalent Inc Com | $12.3M | 0.7% | 100,000 | -88.0% | Trimmed |
Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $1.7B in share positions; options and bonds count in the 13F value but not here.
Biggest buys in Q2 2026
- TNGX Tango Therapeutics Inc. New+$70.3M
- EDIT Editas Medicine Inc. New+$28.8M
- EYPT EyePoint Inc. Added+$25.4M
- Inflarx Nv New+$16.4M
- ASMB Assembly Biosciences Inc. Added+$11.4M
- AVTX Avalo Therapeutics Inc. Added+$9.9M
- COGT Cogent Biosciences Inc. Added+$6.3M
- RLMD Relmada Therapeutics Inc. Added+$5.5M
- Research Alliance Corp Iii Ord Shs Cl A New+$5.3M
- ANTX AN2 Therapeutics Inc. Added+$2.9M
Biggest sells in Q2 2026
- SYRE Spyre Therapeutics Inc. Trimmed-$94.6M
- RLAY Relay Therapeutics Inc. Trimmed-$93.5M
- Nuvalent Inc Com Trimmed-$90.6M
- Alkermes PLC Trimmed-$62.9M
- KYMR Kymera Therapeutics Inc. Trimmed-$57.3M
- ERAS Erasca Inc. Sold out-$51.4M
- CLDX Celldex Therapeutics Inc. Trimmed-$50.1M
- XENE Xenon Pharmaceuticals Inc. Sold out-$48.0M
- NRIX Nurix Therapeutics Inc. Sold out-$35.3M
- CRVS Corvus Pharmaceuticals Inc. Sold out-$33.0M
The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 5 new, 6 added, 9 trimmed, 8 sold out.
Sector mix
- Health Care77.3%
- Not listed with us18.8%
- Industrials3.9%
13F value by quarter
More holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| SABS SAB Biotherapeutics Inc. | $11.2M | 0.7% | 2,870,000 | -34.8% | Trimmed |
| IKT Inhibikase Therapeutics Inc. | $11.0M | 0.7% | 5,397,488 | 0% | Unchanged |
| RLMD Relmada Therapeutics Inc. | $9.9M | 0.6% | 1,425,000 | +124.8% | Added |
| PEPG PepGen Inc. | $8.1M | 0.5% | 4,475,000 | 0% | Unchanged |
| Research Alliance Corp Iii Ord Shs Cl A | $5.3M | 0.3% | 500,000 | New | New |
| Helix Acquisition Corp III | $5.3M | 0.3% | 500,000 | 0% | Unchanged |
| LONA LeonaBio Inc. | $4.3M | 0.3% | 464,398 | 0% | Unchanged |
| VTGN Vistagen Therapeutics Inc. | $630K | 0.0% | 2,788,620 | New | New |
Schedule 13D and 13G filings by Commodore Capital LP
Stakes above 5% of a company, filed within days rather than once a quarter.
- 2026-04-24JATT SCHEDULE 13G filed by JATT II Acquisition CorpSchedule 13G
- 2026-04-02KPTI SCHEDULE 13G filed by Karyopharm Therapeutics Inc.Schedule 13G
- 2026-03-16ANTX SCHEDULE 13G filed by AN2 Therapeutics Inc.Schedule 13G
- 2026-03-11PEPG SCHEDULE 13G filed by PepGen Inc.Schedule 13G
- 2026-01-16IPSC SCHEDULE 13G filed by Century Therapeutics Inc.Schedule 13G
- 2025-10-27ANRO SCHEDULE 13G filed by Alto Neuroscience Inc.Schedule 13G
- 2025-10-03SABS SCHEDULE 13G filed by SAB Biotherapeutics Inc.Schedule 13G
- 2025-05-14TYRA SCHEDULE 13G filed by Tyra Biosciences Inc.Schedule 13G
- 2025-04-11VRDN SCHEDULE 13G filed by Viridian Therapeutics Inc.Schedule 13G
Questions about Commodore Capital LP
- What does Commodore Capital LP own?
- In its Form 13F for Q2 2026, Commodore Capital LP reported 33 holdings worth $1.7B. The five largest were RLAY, ELVN, Alkermes PLC, COGT, AMLX.
- What did Commodore Capital LP buy and sell in Q2 2026?
- Commodore Capital LP opened 5 new positions, added to 6, trimmed 9 and sold out of 8 compared with the quarter before.
- When did Commodore Capital LP file its latest 13F?
- Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed August 14, 2026.
From Form 13F filed by Commodore Capital LP (SEC CIK 0001831942) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds